Tigecycline-Based Regimens for Complicated Urinary Tract Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria: Case Series.
acinetobacter baumannii
bacteremia
carbapenem resistant gram-negatives
klebsiella pneumoniae
tigecycline
urinary tract infections
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jul 2024
Jul 2024
Historique:
accepted:
29
07
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
29
8
2024
Statut:
epublish
Résumé
There is existing controversy regarding the efficacy of tigecycline (TG) in treating complicated urinary tract infections (cUTIs) because of its pharmacokinetic concerns. We present three patients with cUTIs caused by carbapenem-resistant gram-negative (GN) pathogens successfully treated with high-dose tigecycline (HDT)-based regimens, as cefiderocol and aztreonam were not available in our country. The first case describes a 67-year-old patient with diabetes, prostate cancer, and double J ureteral stenting who was hospitalized with a febrile, complicated urinary tract infection (cUTI). Urine and blood cultures were positive for metallo-beta-lactamases (MBL)-producing extensively drug-resistant (XDR)
Identifiants
pubmed: 39205739
doi: 10.7759/cureus.65617
pmc: PMC11350394
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Pagination
e65617Informations de copyright
Copyright © 2024, Niculae et al.
Déclaration de conflit d'intérêts
Human subjects: Consent was obtained or waived by all participants in this study. National Institute for Infectious Diseases Ethic Committee issued approval NA. NA. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Références
Medicine (Baltimore). 2020 Oct 23;99(43):e22638
pubmed: 33120753
Clin Infect Dis. 2010 Mar 1;50(5):625-63
pubmed: 20175247
Transl Androl Urol. 2021 Jan;10(1):292-299
pubmed: 33532318
Clin Microbiol Infect. 2015 May;21 Suppl 1:S1-25
pubmed: 25596784
J Antimicrob Chemother. 2014 Oct;69(10):2606-10
pubmed: 24879669
Antimicrob Agents Chemother. 2014 Jun;58(6):3541-6
pubmed: 24687491
Clin Infect Dis. 2010 Jan 15;50(2):229-38
pubmed: 20025527
J Antimicrob Chemother. 2010 Jun;65(6):1311-2
pubmed: 20378673
J Microbiol Immunol Infect. 2017 Dec;50(6):931-939
pubmed: 28716360
J Antimicrob Chemother. 2016 Oct;71(10):2994-5
pubmed: 27365188
Can J Hosp Pharm. 2012 May;65(3):209-15
pubmed: 22783032
J Pharm Technol. 2014 Jun;30(3):87-92
pubmed: 34860885
Eur J Clin Microbiol Infect Dis. 2022 Jul;41(7):1003-1022
pubmed: 33403565
J Chemother. 2018 Oct - Dec;30(6-8):342-347
pubmed: 30663555
Emerg Microbes Infect. 2020 Dec;9(1):868-885
pubmed: 32284036
Clin Microbiol Infect. 2022 Apr;28(4):521-547
pubmed: 34923128
Antibiotics (Basel). 2023 Jan 21;12(2):
pubmed: 36830145
Clin Ther. 2006 Aug;28(8):1079-1106
pubmed: 16982286
J Hazard Mater. 2023 Sep 15;458:131889
pubmed: 37348375
Infez Med. 2022 Dec 1;30(4):516-524
pubmed: 36482959